1yon Haehling S,Doehner W,Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure[J]. Cardiovasc Res,2007,73(2) :298-309.
6de Denus S, Pharand C, Williamson DR. Brain natriuretie peptide in the management of heart failure: the versatile neurohormone[J]. Chest,2004,125(2) :652-668.
8Cheng V,Kazanagra R,Garcia A,et al. A rapid bedside test for B type peptide treatment outcomes in patients admitted for decompensated heart failure: a pilot study[J]. J Am Coll Cardiol,2001 ,37(8) :386-391.
9Ishii J,Nomura M,Nakamura Y,et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure[J]. Am J Cardiol,2002,89(6):691-695.
10Maisel A. B type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? [J]. Circulation,2002,105(4) :2328-2331.
5Sudon T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature,1988,322:78-81.
6Venugopal J. Cardiac natriuretic peptide-hope or hype? J Clinical Pharmacy Theraperutics, 2001,26:15-31.
7Clerico A, Lervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormaones in humans. Horm Metab Res,1999,31:487-498.
8Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left-ventricular dysfunction.Scand J Clin Invest, 1999,(Supple 230):132-142.
9Sagnella GA. Mearement and significance of circulating natriuretic peptides in cardiovascular disease. Clinical Science,1998,95:519-529.
10Hystad ME, Geiran OR, Attramadal H, et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand,2001,171:395-403.
4Baudhuin LM,Miller WL,Train L,et al.Relation of ADRBI,CYP2D6,and UGTlA1 polymorphisms with dose of,and response to,carvedilol or meto-prolol therapy in patients with chronic heart failure[J].Am J Cardiol,2010,106(3):402-408.
5Petersen M,Andersen JT,Jimenez-SolemE,et al.Effect of specificADRBl /ADRB2/AGT genotype combinations on the association betweensurvival and carvedilol treatment in chronic heart failure:a substudy of theECHOS trial[J],Pharmacogenet Genomics,2012,22(10);709-715.
6Petersen M,Andersen JT,Hjelvang BR,et al.Association of beta-adren-ergic receptor polymorphisms and mortality in carvedilol-treated chronicheart-failure patients[J].Br J Clin Pharmacol,2011,71(4):556-565.
7Ozova EM,Kiiakbaev GK,Kobalava ZD,et al.Effect of carvedilol andmetoprolol R administered with or without atorvastatin on elastic propertiesof vascular wall and parameters of inflammation in patients with chronicheart failure of ischemic origin[J].Kardiologiia,2011,51(4):39-46.
8Ilo H,Nagatomo Y,Kohno T,et al.Differential effects of carvedilol andmetoprolol on renal function in patients with heart failure [J].Circ J,2010,74(8):1578-1583.
9Jabbour A,Macdonald PS,Keogh AM,et al.Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pul-monary disease:a randomized crossover trial[J].J Am Coll Cardiol,2010,55(17):1780-1787.
